The role of phosphatidylinositol 3-kinase signaling pathways in pancreatic cancer

Pancreatology

Volumn 11, Issue 2, 2011, Pages 252-260

  Sun, Chen ^b   Rosendahl, Ann H ^d   Andersson, Roland ^d   Wu, Dequan ^a,b   Wang, Xiangdong ^c  

^a Second Affiliated Hospital   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Pancreatic cancer; PI3K; Signaling pathway

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 5 [5 (4 FLUORO 2 HYDROXYPHENYL)FURFURYLIDENE] 2,4 THIAZOLIDINEDIONE; PHOSPHATIDYLINOSITOL 3 KINASE; WORTMANNIN;

CANCER GROWTH; CELL GROWTH; CELL METABOLISM; CELL MOTILITY; CELL SURVIVAL; ENZYME ACTIVATION; GENE MUTATION; HUMAN; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 79957576837     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000327715     Document Type: Review

References (96)

1. Yao J, Qian C: Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Aktdependent pathway. Med Oncol 2010; 27: 1017-1022.
2. Lockhart AC, Rothenberg ML, Berlin JD: Treatment for pancreatic cancer: Current therapy and continued progress. Gastroenterology 2005; 128: 1642-1654.
3. Schneider G, Siveke JT, Eckel F, Schmid RM: Pancreatic cancer: Basic and clinical aspects. Gastroenterology 2005; 128: 1606-1625.
4. Westphal S, Kalthoff H: Apoptosis: Targets in pancreatic cancer. Mol Cancer 2003; 2: 6.
5. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37(suppl 8):S4-S66.
6. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
7. Fryer RA, Galustian C, Dalgleish AG: Recent advances and developments in treatment strategies against pancreatic cancer. Curr Clin Pharmacol 2009; 4: 102-112.
8. Jonckheere N, Fauquette V, Stechly L, Saint-Laurent N, Aubert S, Susini C, Huet G, Porchet N, Van Seuningen I, Pigny P: Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by ap-2 overexpression. Br J Cancer 2009; 101: 637-644.
9. O'Reilly EM, Abou-Alfa GK: Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 2007; 34: 347-353.
10. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806.
11. Schonleben F, Qiu W, Ciau NT, Ho DJ, Li X, Allendorf JD, Remotti HE, Su GH: Pik3ca mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res 2006; 12: 3851-3855.
12. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N: DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331: 1199-1203.
13. Zhao L, Vogt PK: Class I PI3K in oncogenic cellular transformation. Oncogene 2008; 27: 5486-5496.
14. Solomon B, Pearson RB: Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer. J Thorac Oncol 2009; 4: 787-791.
15. Kierbel A, Gassama-Diagne A, Mostov K, Engel JN: The phosphoinositol-3- kinaseprotein kinase B/Akt pathway is critical for pseudomonas aeruginosa strain PAK internalization. Mol Biol Cell 2005; 16: 2577-2585.
16. Vanhaesebroeck B, Alessi DR: The PI3KPDK1 connection: More than just a road to PKB. Biochem J 2000; 346(Pt 3):561-576.
17. Cantley LC: The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657.
18. Aikin R, Maysinger D, Rosenberg L: Crosstalk between phosphatidylinositol 3-kinase/ Akt and c-Jun NH2-terminal kinase mediates survival of isolated human islets. Endocrinology 2004; 145: 4522-4531.
19. Reichert M, Saur D, Hamacher R, Schmid RM, Schneider G: Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res 2007; 67: 4149-4156.
20. Schild C, Wirth M, Reichert M, Schmid RM, Saur D, Schneider G: PI3K signaling maintains c-Myc expression to regulate transcription of E2F1 in pancreatic cancer cells. Mol Carcinog 2009; 48: 1149-1158.
21. Chaussepied M, Ginsberg D: Transcriptional regulation of Akt activation by E2F. Mol Cell 2004; 16: 831-837.
22. Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, Thorgeirsson SS: E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/ mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology 2008; 135: 1322-1332.
23. Shaw J, Yurkova N, Zhang T, Gang H, Aguilar F, Weidman D, Scramstad C, Weisman H, Kirshenbaum LA: Antagonism of E2F-1 regulated BNIP3 transcription by NF-α B is essential for basal cell survival. Proc Natl Acad Sci USA 2008; 105: 20734-20739.
24. Diehl JA, Cheng M, Roussel MF, Sherr CJ: Glycogen synthase kinase-3 regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12: 3499-3511.
25. Cohen P, Frame S: The renaissance of GSK3. Nat Rev Mol Cell Biol 2001; 2: 769-776.
26. Bader AG, Kang S, Zhao L, Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005; 5: 921-929.
27. Steelman LS, Stadelman KM, Chappell WH, Horn S, Basecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, Mc-Cubrey JA: Akt as a therapeutic target in cancer. Expert Opin Ther Targets 2008; 12: 1139-1165.
28. Zacharek SJ, Xiong Y, Shumway SD: Negative regulation of TSC1-TSC2 by mammalian D-type cyclins. Cancer Res 2005; 65: 11354-11360.
29. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter CL, Kwiatkowski DJ: Loss of TSC1/ TSC2 activates mTOR and disrupts PI3KAkt signaling through downregulation of PDGFR. J Clin Invest 2003; 112: 1223-1233.
30. Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD, Kwiatkowski DJ: PDGFRs are critical for PI3K/ Akt activation and negatively regulated by mTOR. J Clin Invest 2007; 117: 730-738.
31. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF: The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004; 166: 213-223.
32. Shah OJ, Wang Z, Hunter T: Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004; 14: 1650-1656.
33. Ma L, Teruya-Feldstein J, Behrendt N, Chen Z, Noda T, Hino O, Cordon-Cardo C, Pandolfi PP: Genetic analysis of PTEN and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev 2005; 19: 1779-1786.
34. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G, Pederzoli P, Croce CM, Scarpa A: Pancreatic endocrine tumors: Expression profiling evidences a role for Akt-mTOR pathway. J Clin Oncol 2010; 28: 245-255.
35. Asano T, Yao Y, Shin S, McCubrey J, Abbruzzese JL, Reddy SA: Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. Cancer Res 2005; 65: 9164-9168.
36. Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M, Yoshida T: Insulinlike growth factor-I receptor in proliferation and motility of pancreatic cancer. World J Gastroenterol 2010; 16: 1854-1858.
37. Shirk AJ, Kuver R: Epidermal growth factor mediates detachment from and invasion through collagen I and matrigel in capan-1 pancreatic cancer cells. BMC Gastroenterol 2005; 5: 12.
38. Xu Z, Zhang Y, Jiang J, Yang Y, Shi R, Hao B, Zhang Z, Huang Z, Kim JW, Zhang G: Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells. BMC Cancer 2010; 10: 161.
39. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N: MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500-1508.
40. Johnson SK, Haun RS: Insulin-like growth factor binding protein-5 influences pancreatic cancer cell growth. World J Gastroenterol 2009; 15: 3355-3366.
41. Agbunag C, Bar-Sagi D: Oncogenic K-Ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. Cancer Res 2004; 64: 5659-5663.
42. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM: Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKC , but not S6K1. Dev Cell 2006; 11: 859-871.
43. Easton JB, Kurmasheva RT, Houghton PJ: Irs-1: Auditing the effectiveness of mTOR inhibitors. Cancer Cell 2006; 9: 153-155.
44. Thimmaiah KN, Easton J, Huang S, Veverka KA, Germain GS, Harwood FC, Houghton PJ: Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3α-kinase-Akt signaling pathways. Cancer Res 2003; 63: 364-374.
45. Buck E, Eyzaguirre A, Brown E, Petti F, Mc-Cormack S, Haley JD, Iwata KK, Gibson NW, Griffin G: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006; 5: 2676-2684.
46. Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, Abbruzzese JL: Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: Results of two phase II studies. BMC Cancer 2010; 10: 368.
47. Hsu PP, Sabatini DM: Cancer cell metabolism: Warburg and beyond. Cell 2008; 134: 703-707.
48. Kim JH, Park SH, Yu ES, Kim MH, Kim J, Byun JH, Lee SS, Hwang HJ, Hwang JY, Lee MG: Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: Frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations. Radiology 2010; 257: 87-96.
49. Melstrom LG, Salabat MR, Ding XZ, Milam BM, Strouch M, Pelling JC, Bentrem DJ: Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/ Akt pathway in human pancreatic cancer cells. Pancreas 2008; 37: 426-431.
50. Sanchez S, Sayas CL, Lim F, Diaz-Nido J, Avila J, Wandosell F: The inhibition of phosphatidylinositol-3-kinase induces neurite retraction and activates GSK3. J Neurochem 2001; 78: 468-481.
51. Zhang M, Ma Q, Hu H, Zhang D, Li J, Ma G, Bhat K, Wu E: Stem cell factor/c-kit signaling enhances invasion of pancreatic cancer cells via HIF-1 under normoxic condition. Cancer Lett 2011; 303: 108-117.
52. Walter K, Hong SM, Nyhan S, Canto M, Fedarko N, Klein A, Griffith M, Omura N, Medghalchi S, Kuhajda F, Goggins M: Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev 2009; 18: 2380-2385.
53. Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A, Testa JR: Positive feedback regulation between Akt activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 2005; 24: 3574-3582.
54. Edderkaoui M, Nitsche C, Zheng L, Pandol SJ, Gukovsky I, Gukovskaya AS: NADPH oxidase activation in pancreatic cancer cells is mediated through Akt-dependent up-regulation of p22phox. J Biol Chem 2011; 286: 7779-7787.
55. Gerwins P, Skoldenberg E, Claesson-Welsh L: Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 2000; 34: 185-194.
56. Ma J, Sawai H, Ochi N, Matsuo Y, Xu D, Yasuda A, Takahashi H, Wakasugi T, Takeyama H: PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells. Mol Cell Biochem 2009; 331: 161-171.
57. Jiang BH, Zheng JZ, Aoki M, Vogt PK: Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 2000; 97: 1749-1753.
58. Laklai H, Laval S, Dumartin L, Rochaix P, Hagedorn M, Bikfalvi A, Le Guellec S, Delisle MB, Schally AV, Susini C, Pyronnet S, Bousquet C: Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. Proc Natl Acad Sci USA 2009; 106: 17769-17774.
59. Delesque N, Buscail L, Esteve JP, Saint-Laurent N, Muller C, Weckbecker G, Bruns C, Vaysse N, Susini C: Sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res 1997; 57: 956-962.
60. Summy JM, Trevino JG, Baker CH, Gallick GE: C-Src regulates constitutive and EGFmediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas 2005; 31: 263-274.
61. Xiong HQ: Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol 2004; 54(suppl 1):S69-S77.
62. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA: The PI 3-kinase/Akt signaling pathway is activated due to aberrant PTEN expression and targets transcription factors NF-α B and c-Myc in pancreatic cancer cells. Oncogene 2004; 23: 8571-8580.
63. Stoll V, Calleja V, Vassaux G, Downward J, Lemoine NR: Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer. Gut 2005; 54: 109-116.
64. Perugini RA, McDade TP, Vittimberga FJ Jr, Callery MP: Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res 2000; 90: 39-44.
65. Ng SSW, Tsao MS, Chow S, Hedley DW: Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000; 60: 5451-5455.
66. Semba S, Moriya T, Kimura W, Yamakawa M: Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas. Pancreas 2003; 26: 250-257.
67. Takeda A, Osaki M, Adachi K, Honjo S, Ito H: Role of the phosphatidylinositol 3α-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. Pancreas 2004; 28: 353-358.
68. Chen PH, Yang CR: Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF B-dependent pathway. J Immunol 2008; 181: 8441-8449.
69. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of bad couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.
70. Yamada M, Matsuda S, Nakazawa M, Arizono N: Species-specific differences in heterogonic development of serially transferred free-living generations of strongyloides planiceps and strongyloides stercoralis. J Parasitol 1991; 77: 592-594.
71. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, Evan G: Suppression of c-Myc-induced apoptosis by RAS signalling through PI(3)K and PKB. Nature 1997; 385: 544-548.
72. Ng SS, Tsao MS, Nicklee T, Hedley DW: Wortmannin inhibits PKB/Akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 2001; 7: 3269-3275.
73. Fahy BN, Schlieman M, Virudachalam S, Bold RJ: Akt inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 2003; 89: 391-397.
74. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ: Inhibition of Akt abrogates chemotherapy-induced NF B survival mechanisms: Implications for therapy in pancreatic cancer. J Am Coll Surg 2004; 198: 591-599.
75. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ: Inhibition of the phosphatidylinositol 3α-kinase-Akt pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002; 1: 989-997.
76. Binker MG, Binker-Cosen AA, Richards D, Oliver B, Cosen-Binker LI: EGF promotes invasion by PANC-1 cells through Rac1/ROSdependent secretion and activation of MMP-2. Biochem Biophys Res Commun 2009; 379: 445-450.
77. Dise RS, Frey MR, Whitehead RH, Polk DB: Epidermal growth factor stimulates Rac activation through Src and phosphatidylinositol 3-kinase to promote colonic epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2008; 294:G276-G285.
78. Ellenrieder V, Alber B, Lacher U, Hendler SF, Menke A, Boeck W, Wagner M, Wilda M, Friess H, Buchler M, Adler G, Gress TM: Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer 2000; 85: 14-20.
79. Binker MG, Binker-Cosen AA, Richards D, Gaisano HY, de Cosen RH, Cosen-Binker LI: Hypoxia-reoxygenation increase invasiveness of PANC-1 cells through Rac1/MMP-2. Biochem Biophys Res Commun 2010; 393: 371-376.
80. Liau SS, Jazag A, Whang EE: HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res 2006; 66: 11613-11622.
81. Ma J, Sawai H, Matsuo Y, Ochi N, Yasuda A, Takahashi H, Wakasugi T, Funahashi H, Sato M, Takeyama H: IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/ PI3K/Akt signaling pathway in pancreatic cancer cells. J Surg Res 2010; 160: 90-101.
82. Teranishi F, Takahashi N, Gao N, Akamo Y, Takeyama H, Manabe T, Okamoto T: Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo. Cancer Sci 2009; 100: 770-777.
83. Kim S, Kang HY, Nam EH, Choi MS, Zhao XF, Hong CS, Lee JW, Lee JH, Park YK: TMPRSS4 induces invasion and epithelial-mesenchymal transition through upregulation of integrin 5 and its signaling pathways. Carcinogenesis 2010; 31: 597-606.
84. Xia QS, Ishigaki Y, Sun L, Chen R, Motoo Y: Effect of anti-cancer drugs on the expression of BIC/miR-155 in human pancreatic cancer PANC-1 cells (in Chinese). Zhonghua Yi Xue Za Zhi 2010; 90: 123-127.
85. Fujiwara M, Izuishi K, Sano T, Hossain MA, Kimura S, Masaki T, Suzuki Y: Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. J Exp Clin Cancer Res 2008; 27: 76.
86. Liu D, Zhang Y, Dang C, Ma Q, Lee W, Chen W: SiRNA directed against TRKA sensitizes human pancreatic cancer cells to apoptosis induced by gemcitabine through an inactivation of PI3K/Akt-dependent pathway. Oncol Rep 2007; 18: 673-677.
87. Maira SM, Stauffer F, Schnell C, Garcia-Echeverria C: PI3K inhibitors for cancer treatment: Where do we stand? Biochem Soc Trans 2009; 37: 265-272.
88. Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R, Kirkpatrick L, Powis G: Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004; 3: 763-772.
89. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng Q, Durden DL: A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 2008; 68: 206-215.
90. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM: A pharmacological map of the PI3-K family defines a role for p110 in insulin signaling. Cell 2006; 125: 733-747.
91. Knight ZA, Shokat KM: Chemically targeting the PI3K family. Biochem Soc Trans 2007; 35: 245-249.
92. Edling CE, Selvaggi F, Buus R, Maffucci T, Di Sebastiano P, Friess H, Innocenti P, Kocher HM, Falasca M: Key role of phosphoinositide 3-kinase class Ib in pancreatic cancer. Clin Cancer Res 2010; 16: 4928-4937.
93. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7: 1851-1863.
94. Cao P, Maira SM, Garcia-Echeverria C, Hedley DW: Activity of a novel, dual PI3-kinase/ mTOR inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer 2009; 100: 1267-1276.
95. Berna MJ, Tapia JA, Sancho V, Thill M, Pace A, Hoffmann KM, Gonzalez-Fernandez L, Jensen RT: Gastrointestinal growth factors and hormones have divergent effects on Akt activation. Cell Signal 2009; 21: 622-638.
96. Zhou J, Wang CY, Liu T, Wu HS, Zhou F, Xiong JX, Zhao G, Yang M, Yin T, Zhou MT: Phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway is critical for survival and proliferation of pancreatic cancer stem-like side population cells (in Chinese). Zhonghua Yi Xue Za Zhi 2008; 88: 2994-2998.